As the next round of the Trans-Pacific Partnership Agreement (TPP) negotiations continues in Malaysia, MSF urges negotiating countries to reject provisions that threaten to restrict access to affordable medicines for millions of people.

More >

Rohit Malpani, director of policy and advocacy at Doctors Without Borders/Médecins Sans Frontières (MSF)'s Access Campaign, provided witness testimony on June 27, 2013, during a U.S. Congressional hearing on India's trade policies.

More >

MSF International President, Dr. Unni Karunakara, in his keynote speech at the 2012 Universities Allied for Essential Medicines conference:

More >

An open letter to Joe Jiminez and Daniel Vassella, the CEO and President of Novartis, respectively. 

More >

I am writing on behalf of MSF to express our disappointment that J&J has not yet placed any patent into the Medicines Patent Pool and that it has announced in a recent letter to the Medicines Patent Pool that it is not ready to engage in formal negotiations.

More >

NY Times Lettter-to-the-Editor on MSF concerns that a provision in proposed U.S. health care legislation will allow pharmaceutical companies to extend monopolies on high-priced, cutting-edge medicines.

More >

MSF testified at a hearing before the US Trade Representative about the effect of US trade and intellectual property pressures on global health policy and efforts to expand access to affordable medicines in developing countries.

More >

Doctors Without Borders is urging law makers to revise a provision in the U.S. health care legislation that would essentially allow pharmaceutical companies to extend their monopolies on a rapidly expanding and high-priced brand of drugs known as biologics. Biologics--medicines derived from living cells--hold great promise for new vaccines and medicines. Unfortunately, the biologics provision in the current legislation will create a massive barrier to developing generic versions of these cutting-edge drugs.

More >

Statement by Sophie Delaunay Executive Director, MSF-USA

This annual Ministerial review focusing on philanthropy and the Global Health Agenda clearly shows recognition of the urgency to address global health challenges. However, this initiative cannot replace the critical need for greater government leadership to stimulate medical innovation for neglected diseases affecting millions in the poorest corners of the world.

More >

Before the High Level task force communicates its first Comprehensive Framework for Action, Médecins Sans Frontières urges careful consideration of the population that is most vulnerable to the dire consequences of malnutrition – children under two.

More >

Pages